Grant: Idea to Innovation
McGill University
$122,750.00
Rapid, reagent-free technology for identification of methicillin-resistant staphylococcus aureus (MRSA) and vancomycin-resistant entercococci (VRE) in clinical microbiology labs
EF 2016-17
Résumé
Infections caused by antibiotic-resistant bacteria are a major concern in hospitals worldwide. Staphylococcal and enterococcal bacteria are major causes of hospital-acquired infections, including half of all bloodstream infections. Canadian prevalence studies have estimated that approximately 4% of hospitalized patients will become infected or colonized with MRSA (methicillin-resistant Staphylococcus aureus), and the prevalence of infections caused by vancomycin-resistant enterococci (VRE) in Canadian hospitals tripled between 2007 and 2013. One of the recommendations in the action plan on antimicrobial resistance put forward by the Federal government in 2015 is research and development of faster and more accurate diagnostic tools that can provide doctors the information they need to accurately diagnose an infection, thereby promoting effective use of antimicrobials. This NSERC-I2I Phase I proposal aims at achieving these goals by developing a new rapid and cost-effective technology for the identification of MRSA and VRE based on ""whole-organism fingerprinting"" by attenuated total reflectance-Fourier transform infrared (ATR-FTIR) spectroscopy. The advantages of the new technology include: (i) minimal sample preparation, (ii) reagent-free analysis, (iii) simple (one-step) protocol, (iv) fast turnaround time (1-2 min), and (v) low cost per test. To our knowledge, there is no other technology currently on the market that accomplishes the discrimination between antibiotic-resistant and antibiotic-susceptible bacteria in a single step without the use of any reagents.
Programme
Idea to Innovation
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
500176-2016
Name nom
Ismail, Ashraf
Department département
Food Science and Agricultural Chemistry
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2016
Award amount
122750
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
3403
Research subject group en
Physical chemistry
Research subject group fr
Chimie physique
Research subject en
Spectroscopy
Research subject fr
Spectroscopie
Partie
1
Nb partie
1
Application title
Rapid, reagent-free technology for identification of methicillin-resistant staphylococcus aureus (MRSA) and vancomycin-resistant entercococci (VRE) in clinical microbiology labs
Keyword
NSERC
Application summary
Infections caused by antibiotic-resistant bacteria are a major concern in hospitals worldwide. Staphylococcal and enterococcal bacteria are major causes of hospital-acquired infections, including half of all bloodstream infections. Canadian prevalence studies have estimated that approximately 4% of hospitalized patients will become infected or colonized with MRSA (methicillin-resistant Staphylococcus aureus), and the prevalence of infections caused by vancomycin-resistant enterococci (VRE) in Canadian hospitals tripled between 2007 and 2013. One of the recommendations in the action plan on antimicrobial resistance put forward by the Federal government in 2015 is research and development of faster and more accurate diagnostic tools that can provide doctors the information they need to accurately diagnose an infection, thereby promoting effective use of antimicrobials. This NSERC-I2I Phase I proposal aims at achieving these goals by developing a new rapid and cost-effective technology for the identification of MRSA and VRE based on ""whole-organism fingerprinting"" by attenuated total reflectance-Fourier transform infrared (ATR-FTIR) spectroscopy. The advantages of the new technology include: (i) minimal sample preparation, (ii) reagent-free analysis, (iii) simple (one-step) protocol, (iv) fast turnaround time (1-2 min), and (v) low cost per test. To our knowledge, there is no other technology currently on the market that accomplishes the discrimination between antibiotic-resistant and antibiotic-susceptible bacteria in a single step without the use of any reagents.